Saturday 17 October 2026
Export HYPD’s income statement to Excel — free account
Hyperion DeFi, Inc.
HYPD Healthcare Biotechnology
Hyperion DeFi, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $813,500.00, up 1,319.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,333.3%, EPS grew 140.4%, free cash flow grew 86.8% and total debt rose 12.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.84
0.31
−9.84%
Follow HYPD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
31.77 | 34.61 | 21.15 | 166.46 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(15.36) | (8.72) | (4.39) | (20.46) | |
P/B ratio |
0.44 | 0.63 | 0.43 | 0.82 | |
Price to Tangible BV |
0.58 | 0.86 | 0.87 | 1.62 | |
EV/Sales |
30.92 | 42.99 | 33.94 | 191.57 | |
EV/EBITDA |
8.85 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.10) | (3.13) | (1.93) | (3.95) | |
EV/FCF |
(0.56) | (0.57) | (0.36) | (0.81) | |
Quick Ratio |
1.75 | 1.65 | 2.34 | 2.04 | |
Current Ratio |
2.34 | 1.97 | 2.68 | 2.25 | |
Net Debt/EBITDA |
(0.04) | (0.05) | (0.04) | (0.13) | |
Debt/Assets |
7.46% | 9.94% | 15.06% | 9.25% | |
Debt/Equity |
0.08 | 0.12 | 0.19 | 0.11 | |
Asset Turnover |
0.02 | 0.03 | 0.03 | 0.01 | |
Operating CF/Net income |
(0.20) | (1.30) | 0.10 | (0.48) | |
Capex/Depreciation |
(120.79) | 0.00 | 0.00 | (1,182.20) | |
Interest Coverage |
132.62 | 38.65 | (176.89) | 19.85 | |
Research and Development Expense of Revenue |
16.35% | 117.40% | 38.09% | 123.60% | |
Selling, General and Administrative Expense of Revenue |
1,095.50% | 1,839.38% | 913.04% | 857.55% | |
Intangible Assets out of Total Assets |
0.23 | 0.23 | 0.40 | 0.42 | |
Share Based Compensation of Revenue |
456.33% | 738.64% | 355.84% | (445.29%) | |
Graham Net Nets |
0.04 | (0.08) | (0.19) | (0.05) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(197.13%) | (281.16%) | (325.56%) | (200.11%) | |
Free Cash Flow Yield |
(173.40%) | (218.98%) | (451.70%) | (142.80%) | |
Revenue per Share |
0.03 | 0.02 | 0.10 | 0.05 | |
Operating CF per Share |
(0.20) | (0.40) | (0.81) | (0.47) | |
Capex per Share |
0.17 | 0.00 | 0.00 | (10.89) | |
Free Cash Flow per Share |
(0.03) | (0.40) | (0.81) | (11.35) | |
Cash per Share |
0.68 | 0.70 | 1.26 | 1.36 | |
Shareholders Equity per Share |
7.19 | 5.51 | 8.21 | 11.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.19 | 5.51 | 8.21 | 11.74 | |
Free Cash Flow |
(0.46) | (4.20) | (4.06) | (68.43) | |
Working Capital |
7.40 | 4.33 | 4.54 | 5.05 | |
Capital Expenditures |
2.44 | — | — | (65.61) | |
Net Current Asset Value |
1.70 | (2.77) | (3.46) | (2.95) | |
EV/EBIT |
9.84 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(6.82) | 0.00 | 0.00 | 216.90 | |
Price to Operating Income |
10.11 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.52 | 0.81 | 1.14 | 1.36 | |
Average Assets |
84.40 | 38.03 | 27.72 | 52.79 | |
Average Common Equity |
69.65 | 24.39 | 13.98 | 37.24 |
Columns are period end dates